The report provides an in-depth assessment of the HIV market including disease overview, epidemiology, disease management, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, current and future players, and market outlook.
Over four decades ago, researchers identified the human immunodeficiency virus (HIV) as the causative agent of a then-mysterious new illness, acquired immunodeficiency syndrome (AIDS). A member of the Lentivirus genus, HIV belongs to the family of retroviruses, RNA viruses with the ability to reverse transcribe their single-stranded RNA genome into double-stranded DNA and integrate it into the host’s genome (Barré-Sinoussi et al., 1983; Gallo et al., 1983; McCutchan et al., 1996). Since the start of the epidemic, around 88.4 million people have become infected, and 42.3 million have died from AIDS-related illnesses (UNAIDS, 2024). In the decades since the approval of the first antiretroviral therapy (ART)-GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine) in 1987-the HIV market has become highly competitive, with a wide range of options now available for both treatment and prophylaxis of HIV. This includes the availability of once-daily, single-tablet regimens (STRs) for HIV treatment such as Gilead's Biktarvy (bictegravir/emtricitabine/TAF) and Genvoya (elvitegravir/cobicistat/emtricitabine/TAF), as well as long-acting injectables including Gilead's Sunlenca (lenacapavir) for the treatment of multidrug-resistant HIV, as well as GSK's Apretude (cabotegravir) and Gilead's Yeztugo/Yeytuo (lenacapavir) for pre-exposure prophylaxis (PrEP).
The analyst projects the global HIV marketplace-which, for the purposes of this report, comprises seven major pharmaceutical markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan)-to experience modest growth during the forecast period. The report covers only HIV-1 because the strain is responsible for the majority of diagnosed prevalent cases of HIV in the 7MM. Furthermore, HIV-2 infections are mainly reported in sub-Saharan African countries, which are not included in the scope of this report.
The model covers the market forecast for marketed products and Phase III pipeline products. The base year of this model is 2023, and the forecast period is 2023-33.
Over four decades ago, researchers identified the human immunodeficiency virus (HIV) as the causative agent of a then-mysterious new illness, acquired immunodeficiency syndrome (AIDS). A member of the Lentivirus genus, HIV belongs to the family of retroviruses, RNA viruses with the ability to reverse transcribe their single-stranded RNA genome into double-stranded DNA and integrate it into the host’s genome (Barré-Sinoussi et al., 1983; Gallo et al., 1983; McCutchan et al., 1996). Since the start of the epidemic, around 88.4 million people have become infected, and 42.3 million have died from AIDS-related illnesses (UNAIDS, 2024). In the decades since the approval of the first antiretroviral therapy (ART)-GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine) in 1987-the HIV market has become highly competitive, with a wide range of options now available for both treatment and prophylaxis of HIV. This includes the availability of once-daily, single-tablet regimens (STRs) for HIV treatment such as Gilead's Biktarvy (bictegravir/emtricitabine/TAF) and Genvoya (elvitegravir/cobicistat/emtricitabine/TAF), as well as long-acting injectables including Gilead's Sunlenca (lenacapavir) for the treatment of multidrug-resistant HIV, as well as GSK's Apretude (cabotegravir) and Gilead's Yeztugo/Yeytuo (lenacapavir) for pre-exposure prophylaxis (PrEP).
The analyst projects the global HIV marketplace-which, for the purposes of this report, comprises seven major pharmaceutical markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan)-to experience modest growth during the forecast period. The report covers only HIV-1 because the strain is responsible for the majority of diagnosed prevalent cases of HIV in the 7MM. Furthermore, HIV-2 infections are mainly reported in sub-Saharan African countries, which are not included in the scope of this report.
The model covers the market forecast for marketed products and Phase III pipeline products. The base year of this model is 2023, and the forecast period is 2023-33.
Key Highlights
- Report deliverables include a Pdf report and an Excel-based forecast model
- Forecast includes the 7 major markets (7MM)
- Forecast covers the period 2023-2033
Report Scope
- Overview of HIV including etiology, pathophysiology and epidemiology.
- Key topics covered include current market landscape, strategic competitor assessment, unmet needs and opportunities, R&D trends, pipeline assessment, and current and future players.
- HIV market outlook from 2023-2033, including annual cost of therapy per patient, and total sales revenues per product for each of the 7MM.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and identify the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the 7MM HIV market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM HIV market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 HIV: Executive Summary
2 Introduction
3 Disease Overview
4 Epidemiology
5 Disease Management
6 Current Treatment Options
7 Unmet Needs and Opportunity Assessment
8 R&D Strategies
9 Pipeline Assessment
10 Pipeline Valuation Analysis
11 Current and Future Players
12 Market Outlook
13 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Gilead
- Janssen
- Merck
- ViiV Healthcare
- GSK
- AbbVie
- Theratechnologies
- Roche
- Cytodyn
